Xeris Biopharma Holdings (XERS) Free Cash Flow (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Free Cash Flow came in at $9.9 million in Q1 2026, up 198.39% YoY from $3.3 million in Q1 2025, and down 50.76% on a QoQ basis from $20.0 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Free Cash Flow (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Free Cash Flow data on file, last reported at $9.9 million in Q1 2026.
- Quarterly Free Cash Flow rose 198.39% year-over-year to $9.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.5 million (up 281.69% YoY) and the FY2025 annual result came in at $28.6 million, up 177.41% from the prior year.
- Free Cash Flow declined to $9.9 million in Q1 2026, from $20.0 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $20.0 million in Q4 2025 to a low of -$48.4 million in Q1 2022.
- A 5-year average of -$8.7 million and a median of -$10.3 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow tumbled 102.07% — and 2025, when it soared 914.84%.
- Tracing XERS's Free Cash Flow over 5 years: stood at -$16.1 million in 2022, then jumped by 146.35% to $7.5 million in 2023, then slumped by 73.56% to $2.0 million in 2024, then soared by 914.84% to $20.0 million in 2025, then slumped by 50.76% to $9.9 million in 2026.
- The last three Free Cash Flow figures came in at $9.9 million (Q1 2026), $20.0 million (Q4 2025), and $18.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 307.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 538.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.14 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 205.60 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 329.00 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 128.60 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 244.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.51 Bn | 1.39 Bn | 79.59 Mn | 8.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.26 Mn |
| Jun 30, 2026 | 8.26 Mn |
| Mar 31, 2026 | 9.87 Mn |
| Mar 31, 2026 | 9.87 Mn |
| Dec 31, 2025 | 20.04 Mn |
| Dec 31, 2025 | 20.04 Mn |
| Sep 30, 2025 | 18.43 Mn |
| Sep 30, 2025 | 18.43 Mn |
| Jun 30, 2025 | 182,000.00 |
| Jun 30, 2025 | 182,000.00 |
| Mar 31, 2025 | -10.03 Mn |
| Mar 31, 2025 | -10.03 Mn |
| Dec 31, 2024 | 1.98 Mn |
| Dec 31, 2024 | 1.98 Mn |
| Sep 30, 2024 | -8.31 Mn |
| Sep 30, 2024 | -8.31 Mn |
| Jun 30, 2024 | -10.35 Mn |
| Jun 30, 2024 | -10.35 Mn |
| Mar 31, 2024 | -20.30 Mn |
| Mar 31, 2024 | -20.30 Mn |